secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001650664-25-000106
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports 58% HBG1/2 editing in NHPs after single tLNP dose at 5 months
----------------------------------------------------------------------------

- Mean on-target editing of 58% in HSCs at 5 months post single IV dose of proprietary tLNP, exceeding ≥25% therapeutic threshold.
- Data presented at EHA 2025; supports in vivo approach for sickle cell disease and beta thalassemia.
- Biodistribution shows significant liver de-targeting vs. standard LNPs in NHPs.
- Uses AsCas12a to edit HBG1/2 promoters, mimicking hereditary persistence of fetal hemoglobin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000106/0001650664-25-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000106/edit-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer